Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $238 (market cap $44.01B). The key difference: TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock is far larger — about 5.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | TTWO | |
|---|---|---|
Market Cap | $8.04B | $44.01B |
Sector | Health | Media |
52-Week High | $339.75 | $262.29 |
52-Week Low | $241.71 | $189.69 |
Enterprise Value | $7.85B | $44.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Take-Two Interactive (TTWO) trades at $244.10, up 0.37% on the day, with a bullish technical outlook supported by moving averages and ADX signals. The stock has consistently beaten earnings expectations in recent quarters, though it reported a net loss of -$4.48 billion in FY2025. Sentiment is highly positive due to strong pre-orders for Grand Theft Auto VI, priced at $79.99 with a November 2026 launch, driving analyst optimism.
The outlook is driven by GTA VI's monetization potential, with a consensus price target of $302.50 implying 24% upside. Risks include high debt levels, negative profitability, and execution challenges. Institutional confidence remains strong with 79% buy ratings, but investors should monitor cash flow trends and competitive pressures in the gaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
